Transcatheter Cardiovascular Therapeutics (TCT)

The Transcatheter Cardiovascular Therapeutics (TCT) conference is the Cardiovascular Research Foundation's (CRF) annual scientific symposium and the largest conference focused on interventional cardiovascular medicine. TCT includes seminars on all areas of intervention cardiology, structural heart, vascular in interventions, peripheral artery disease, and other procedures in the cath lab.

Cardiologist shares his long journey from Libya to United States
Abdel Almanfi, MD, went through years of training in Libya, but then he had to start over once he landed in the United States.
Cardiologists share historic research that led to FDA’s long-awaited approval of coronary DCB
When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing.
Why financial literacy is so important for structural heart program directors
Carrie Redick, an ICU nurse for nearly 20 years, said understanding more about financial data improved her ability to acquire funding and other resources for her program when necessary.
Data registries have been a huge success for U.S. structural heart programs
ACC/STS National Cardiovascular Data Registry metrics reporting for TAVR is important for marketing and care quality, explains Patricia Keegan, NP, with the Emory Heart and Vascular Center.
CroíValve kicks off early feasibility study for new TR device, names cardiologist Martin Leon to advisory board
The company hopes to enroll 15 patients to monitor the safety and effectiveness of its new-look transcatheter device for severe tricuspid regurgitation.

Researchers presented their findings at TCT 2021, noting that TAVR and surgery had similar mortality rates after five years.

November 5, 2021

The analysis, presented at TCT 2021, examined total costs after two years for more than 900 patients who underwent TAVR or SAVR.

November 5, 2021

The analysis, presented at TCT 2021, included input from 400 patients with high blood pressure.

November 4, 2021

The findings were presented at TCT 2021 and published in the New England Journal of Medicine.

November 4, 2021

The three-day event is sponsored by the Cardiovascular Research Foundation.

October 26, 2021

New two-year findings, presented at TVT 2021, suggest that the Watchman FLX device is a safe alternative to long-term oral anticoagulation therapy.

July 23, 2021

The findings were presented Friday, Oct. 16, at TCT Connect 2020.

October 16, 2020

The findings were presented Thursday, Oct. 15, at TCT Connect 2020.

October 15, 2020